

Current Research

SECTION	CENTER	PI	PROJECT_TITLE	DIRECT_SPONSOR
	Cancer Research Center	Nayak-Kapoor, Asha	A Phase IB, Open-Label, Multicenter Study to Investigate the Effect of Oral LBH589 on Dextromethorphan, a CYP2D6 Substrate, and to Stress the Efficacy and Safety of Oral LBH589 in Patients with Advanced Solid Tumors	Novartis
	Molecular Chaperone	Horuzsko, Anatolij	Prolongation of Allograft Survival By Inhibitory Receptors for HLA-G	Roche Organ Transplantation Research Foundation
	Molecular Chaperone	Horuzsko, Anatolij	Prolongation of Allograft Survival By Inhibitory Receptors for HLA-G	Roche Organ Transplantation Research Foundation
Cardiology		Robinson, Vincent J.	A Prospective, Randomised, Double-Blind, Double-Dummy, Parallel Group, Multicenter, Event Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivarobaxban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects with Non-Valvular Atrial Fibrillation	Johnson & Johnson Pharmaceutical R&D
Cardiology		Robinson, Vincent J.	A Prospective, Randomised, Double-Blind, Double-Dummy, Parallel Group, Multicenter, Event Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivarobaxban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects with Non-Valvular Atrial Fibrillation	Johnson & Johnson Pharmaceutical R&D
Cardiology		Thornton, John	HOME AUTOMATIC EXTERNAL DEFIBRILLATOR TRIAL -H.A.T.	Seattle Institute for Cardiac Research
Nephrology		Mulloy, Laura	An Open Label, Prospective, Randomized, Controlled, Multi-Center Study Assessing Fixed Dose Vs. Concentration Controlled CellCept Regimens for Patients Following a Single Organ Renal Transplantation in Combination with Full Dose and Reduced Dose Calcineurin Inhibitors	Roche Laboratories
Hematology/Oncology	Cancer Research Center	Samuel, Thomas	A Phase 2, Two-Arm, Double-Blind, Multicenter, Randomized Study of the Combination of Oral WX-671 Plus Capecitabine vs Capecitabine Monotherapy in First-Line HER2-Negative Metastatic Breast Cancer	Wilex
		Sazonova, Irina	Molecular Chimerization of Plasmin: Comparative Effects on Thrombolysis of Embolic Cerebral Ischemia	American Heart Association
Hematology/Oncology	Cancer Research Center	Bhalla, Kapil	A Phase II Study of MK-0457 in Patients with BCR-ABL T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia	Merck & Company
	Immunotherapy Center	Mellor, Andrew	Genetic Manipulation to Prolong Transplant Survival and Reduce Dependence on Global Immunosuppressive Drugs	MCG Foundation

Current Research

	IMMAG	Bollag, Wendy	Phospholipase D and Keratinocyte Differentiation (Research Supplement to Promote Diversity in Health-Related Research - LAKIEA BAILEY)	National Institute of Arthritis & Musculoskeletal & Skin Diseases/ NIH/ DHHS
	Immunotherapy Center	Mellor, Andrew	Creating Local Suppressive Inflammation to Block T1D Progression	Juvenile Diabetes Research Foundation International
		Jillella, Anand	CLO-24300606 - A Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) for whom Standard Induction Chemotherapy is Unlikely to be of Benefit	Genzyme Corporation
		Jillella, Anand	An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients with Imatinib (Glivec®/Gleevec®) -Resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase	Novartis
	IMMAG	Dynan, William	Laser Capture Microscopy and 2D-DIGE: Cancer Proteomics	National Cancer Institute/ NIH/ DHHS
		Berman, Adam	Lead and Delivery Tools (LAND-IT) Registry	St. Jude Medical
	Cancer Research Center	He, Yukai	Mechanism of Eliciting Antitumor Cell Immunity Via Lentivector Immunization	National Cancer Institute/ NIH/ DHHS
Pulmonary Disease		Gossage, James	A Phase III, Randomised, Double-Blind, Parallel-Group Study of the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg bid) Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism, Following Initial Treatment (5-10 Days) with a Parental Anticoagulant Approved for this Indication - RE-COVER	Boehringer Ingelheim
	Cancer Research Center	Jillella, Anand	A Phase II Study of Oral Panobinostat in Adult Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma after Failure of High-Dose Chemotherapy with Autologous Stem Cell Transfusion and a Gemcitabine-or Vinorelbine-or Vinblastine-Containing Treatment Regimen	Novartis
Rheumatology		Moore, Walter	Systemic Lupus Erythematosus in Gullah Health (SLEIGH)	Medical University of South Carolina
Hematology/Oncology	Cancer Research Center	Bhalla, Kapil	A Phase IA/II, Two-Arm, Multi-Center, Open-Label, Dose Escalation Study of LBH589 Administered Orally via Different Dosing Schedules in Adult Patients with Advanced Hematological Malignancies	Novartis

Current Research

Hematology/ Oncology	Cancer Research Center	Bhalla, Kapil	A Phase IA/II, Two-Arm, Multi-Center, Open-Label, Dose Escalation Study of LBH589 Administered Orally via Different Dosing Schedules in Adult Patients with Advanced Hematological Malignancies	Novartis
	Immunotherapy Center	Koni, Pandelakis	Antibody-Dependent Cellular Cytotoxicity Targeted Against HIV-1 Env Glycans	Gates (Bill & Melinda) Foundation
Hematology/ Oncology	Cancer Research Center	Natarajan, Kavita	A Phase II Study of Oral LBH589 in Adult Patients with Refractory Cutaneous T-Cell Lymphoma and Prior HDAC Inhibitor Therapy(Clinical Trial Protocol CLBH589B2212)	Novartis
Pulmonary Disease		Gossage, James	Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding	Research Corporation of Long Island, NY
Hematology/ Oncology		Natarajan, Kavita	Adult Hemophilia Program Grant - To Cover Expenditures as Proposed	Hemophilia of Georgia
	Center for Biotech.& Genomic Med.	Pacholczyk, Rafal	Pathogenic Th17 Cells in Diabetes During Oral Vaccination (STP Mentor: Leszek Ignatowicz)	Intramural Grant Program
Pulmonary Disease		Gossage, James	A Double-Blind Extension Study to Evaluate the Long-Term Safety and Efficacy of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension	Lilly ICOS
Nephrology		Mulloy, Laura	A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in De Novo Kidney Transplant Recipients	Astellas Pharma USA
		Berman, Adam	Correlation of Pace-Mapping of Ventricular Tachycardia and Complex Fractionated Electrogram Distribution During Ablation of Ischemic Ventricular Tachycardia Using NAVX Mapping (VT CFE)	St. Jude Medical
Nephrology		Jagadeesan, Muralidharan	A Double-Blind, Randomized, Stratified, Multi-Center Trial Evaluating the Conventional and High Dose Oseltamivir in the Treatment of Immunocompromised Patients with Influenza	Roche Laboratories
Nephrology		Jagadeesan, Muralidharan	A Double-Blind, Randomized, Stratified, Multi-Center Trial Evaluating the Conventional and High Dose Oseltamivir in the Treatment of Immunocompromised Patients with Influenza	Roche Laboratories
Cardiology		Wiles, Henry	STARFlex in Atrial Septal Defect (ASD) - Long Term Status Assessment of Patient Enrolled in the STARFlex Septal Occlusion System ASD Closure IDE Studies: G-960098; NMT Study Numbers: 99-1; 00-1	NMT Medical, Inc.

Current Research

Hematology/ Oncology	Cancer Research Center	Natarajan, Kavita	A Phase II Study of Oral LBH589 in Adult Patients with Refractory Cutaneous T-Cell Lymphoma (Study Protocol # CLBH589B2201)	Novartis
		Gladysheva, Inna	Regulation of Structure and Activity of the Cardiomyocyte Specific pro-ANP Convertase, Corin by Mast Cell Proteases	American Heart Association
		Coleman, Teresa	A Multicenter, Randomized, Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflune/Gemcitabine to Placebo/Gemcitabine in Patients who are Ineligible to Receive Cisplatin-Based Therapy (VINCENT)	Bristol-Myers Squibb Company
Cardiology		Robinson, Vincent J.	A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Simvastatin Combination Therapy to Fenofibric Acid and Simvastatin Monotherapy in Subjects with Mild Dyslipidemia	Abbott Laboratories Fund
Cardiology		Wiles, Henry	STARFlex in Atrial Septal Defect (ASD) - Long Term Status Assessment of Patient Enrolled in the STARFlex Septal Occlusion System ASD Closure IDE Studies: G-960098; NMT Study Numbers: 99-1; 00-1	NMT Medical, Inc.
	IMMAG	Bollag, Wendy	Phosphatidylglycerol and Corneal Wound Healing	Intramural Grant Program
Hematology/ Oncology	Cancer Research Center	Samuel, Thomas	Phase I/II Study of a Combination of Suberoylanilide Hydroxyamic Acid (Vorinostat) Plus Paclitaxel and Bevacizumab in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent Breast Cancer	Montefiore Medical Center
	Cancer Research Center	Jillella, Anand	Phase 2/3 Randomized, Open Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients with Relapsed-Refractory Multiple Myeloma	Kosan Biosciences
	Center for Biotech.& Genomic Med.	Ignatowicz, Leszek	Origin and Dynamic Allocation of Antigen Specific Foxp3+ T Cells Upon Graft Rejection or Acceptance	Roche Organ Transplantation Research Foundation
Cardiology		Reed, Guy	Secretion in Vascular Inflammation and Thrombosis	National Heart, Lung, & Blood Institute/ NIH/ DHHS
Hematology/ Oncology		Jillella, Anand	National Surgical Adjuvant Breast and Bowel Project	NSABP Foundation
Hematology/ Oncology		Jillella, Anand	National Surgical Adjuvant Breast and Bowel Project	NSABP Foundation
Hematology/ Oncology	Cancer Research Center	Samuel, Thomas	A Phase I-II Study of R115777 (Tipifarnib, Zarnestra) Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients with Stage IIB-IIIC Breast Cancer	Montefiore Medical Center

Current Research

	Center for Biotech.& Genomic Med.	Kraj, Piotr	Foxp3+ CD4+ Regulatory T Cells in Type I Diabetes	Juvenile Diabetes Research Foundation International
		Mulloy, Laura	A Randomized, Open-Label, Multicenter, Parallel Group Study of Belatacept-Based Corticosteroid-Free Regimens in Renal Transplant	Bristol-Myers Squibb Company
		Mulloy, Laura	A Randomized, Open-Label, Multicenter, Parallel Group Study of Belatacept-Based Corticosteroid-Free Regimens in Renal Transplant	Bristol-Myers Squibb Company
	Center for Biotech.& Genomic Med.	Kraj, Piotr	CD4+T Cell Subset Function in Antitumor Immune Response	National Cancer Institute/ NIH/ DHHS
	Immunotherapy Center	Mellor, Andrew	T Cell Regulation by IDO-Competent Plasmacytoid Dendritic Cells	National Institute of Allergy & Infectious Diseases/ NIH/ DHHS
Hematology/Oncology	Cancer Research Center	Samuel, Thomas	A Phase 1/2 Study to Investigate the Safety, Tolerability and Potential Activity of IPI-504 in Relapsed and/or Refractory Stage IIIb (with Malignant Pleural or Pericardial Effusion), or Stage IV NSCLC Patients	Infinity Pharmaceuticals
Hematology/Oncology	Cancer Research Center	Samuel, Thomas	A Phase 1/2 Study to Investigate the Safety, Tolerability and Potential Activity of IPI-504 in Relapsed and/or Refractory Stage IIIb (with Malignant Pleural or Pericardial Effusion), or Stage IV NSCLC Patients	Infinity Pharmaceuticals
	Immunotherapy Center	Mellor, Andrew	IDO Dependent T Cell Suppression	National Institute of Allergy & Infectious Diseases/ NIH/ DHHS
	IMMAG	Dynan, William	Nanomedicine Center for Nucleoprotein Machines	Georgia Institute of Technology
Infectious Diseases		Rissing, J. Peter	An International, Multicenter, Prospective Observational Study of the Safety of Maraviroc Used with Optimized Background Therapy in Treatment-Experienced HIV-1 Infected Patients	Pfizer Pharmaceuticals
Hematology/Oncology	Cancer Research Center	Ustun, Celalettin	A Single-Arm, Phase II, Open-Label Study to Determine the Efficacy of 100 mg Twice Daily Oral Dosing of Midostaurin Administered to Patients with Aggressive Systemic Mastocytosis or Mast Cell Leukemia +/- an Associated Hematological Clonal Non-Mast Cell Lineage Disease	Novartis
		Mulloy, Laura	A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf/MMF, Modified Release (MR) Tacrolimus/MMF and Neoral/MMF in de novo Kidney Transplant Recipients	Fujisawa USA, Inc.

Current Research

		Jillella, Anand	MCG Minority-Based Community Clinical Oncology Program	National Cancer Institute/ NIH/ DHHS
Hematology/ Oncology		Kutlar, Abdullah	A One Year Open Label, Non-Comparative Extension to a Randomized, Multicenter, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and the Effects on Liver Iron Concentration of Repeated Doses of 5-30 mg/kg/day of ICL670 Relative to Deferoxamine in Sickle Cell Disease Patients with Transfusional Hemosiderosis	Novartis
Hematology/ Oncology		Kutlar, Abdullah	A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Tolerability and Pharmacokinetics of HQK-1001 in Subjects with Sickle Cell Disease	HemaQuest Pharmaceuticals, Inc.
		Kapoor, Deepak	PROTECT II: A Prospective, Multi-Center, Randomized Controlled Trial of the IMPELLA RECOVER LP 2.5 System Versus Intra Aortic Balloon Pump (IABP) in Patients Undergoing Non Emergent High Risk PCI	Abiomed, Inc.
Hematology/ Oncology		Kutlar, Abdullah	Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Hematology and Biochemistry Core Laboratory	Clinical Trials & Surveys Corp.
Nephrology		Mulloy, Laura	A 24 month, randomized, multi-center, open label non-inferiority study of efficacy and safety comparing concentration-controlled Certican in two doses (1.5 and 3.0 mg/day starting doses) with reduced Neoral versus 1.44 mg Myfortic with standard dose Neoral in de novo renal transplant recipients	Novartis
Nephrology		Mulloy, Laura	A 24 month, randomized, multi-center, open label non-inferiority study of efficacy and safety comparing concentration-controlled Certican in two doses (1.5 and 3.0 mg/day starting doses) with reduced Neoral versus 1.44 mg Myfortic with standard dose Neoral in de novo renal transplant recipients	Novartis
		Mulloy, Laura	A Phase 3, Randomized, Active-Controlled, Open-Label, Multi-Center Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated with Epoetin Alfa	Fresenius Medical Care Holdings
	Cancer Research Center	Jillella, Anand	A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of SNX-5422 Mesylate in Subjects with Refractory Hematological Malignancies	Serenex/Pfizer Pharmaceuticals
	IMMAG	Dynan, William	Regulation of DNA Double-Strand Break Repair	National Cancer Institute/ NIH/ DHHS
Hematology/ Oncology	Cancer Research Center	Bhalla, Kapil	Heat Shock Protein 90 Antagonist-Based Therapy of Mantle Cell Lymphoma	National Cancer Institute/ NIH/ DHHS
		Goggans, Donald	CHI Renewal and Reaffirmation of Agreement 2005	Blue Cross/ Blue Shield of Georgia Foundation

Current Research

Infectious Diseases		Rissing, J. Peter	OP Early Intervention Services with Respect to HIV Disease	Health Resources & Services Administration/ DHHS
	Molecular Chaperone	Moskofidis, Dimitrios	Function of HSPs in Mouse Models for Human Diseases	National Cancer Institute/ NIH/ DHHS
		Szerlip, Harold	Cardiovascular Outcomes in Renal Atherosclerotic Lesions	University of Toledo
Pulmonary Disease		Gossage, James	A Multinational, Multicentre, Randomized, Parallel Group, Double-Blind Study to Assess the Efficacy and Safety of 1mg, 5mg and 20mg TID of Oral Sildenafil in the Treatment of Subjects Aged 18 Years and Over with Pulmonary Arterial Hypertension (PAH)	Pfizer Pharmaceuticals
Hematology/ Oncology		Kutlar, Abdullah	NCMHD Southeastern Exploratory Sickle Cell Center of Excellence	National Center on Minority Health and Health Disparities/NIH/DHHS
Hematology/ Oncology	Cancer Research Center	Bhalla, Kapil	Histone Deacetylase Inhibitors in CML	National Cancer Institute/ NIH/ DHHS
	Molecular Chaperone	Chadli, Ahmed	Understanding the Role of the Co-Chaperone GCUNC45 in the Hsp90 Chaperoning Pathway	American Heart Association
		Jillella, Anand	A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib Versus Sorafenib Versus Placebo in Patients with Resected Renal Cell Carcinoma	Eastern Coop Oncology Group
Rheumatology	Center for Patient and Family Centered Care	Moore, Walter	Improving Patient Rounds (IPR): Patient-and Family-Centered Care Takes on Academic Bedside Rounds	Picker Institute
	Cancer Research Center	May, Amanda	A Phase I/II, Open-Label, Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RAF265 (CHIR-265) Administered Orally to Patients with Locally Advanced or Metastatic Melanoma	Novartis
	Immunotherapy Center	Mellor, Andrew	Regulation of T Cell Immunity by Indoleamine 2,3 Dioxygenase (IDO)	Newlink Genetics
	IMMAG	Bollag, Wendy	Phospholipase D and Keratinocyte Differentiation	National Institute of Arthritis & Musculoskeletal & Skin Diseases/ NIH/ DHHS

Current Research

	Molecular Chaperone	Kamitani, Tetsu	The Role of NUB1 in Pathogenesis of Parkinson's Disease	National Institute on Aging/ NIH/ DHHS
	Immunotherapy Center	Mellor, Andrew	Innovative Approaches To Prolong Transplant Survival and Reduce the Fiscal and Health Burden of Long Term Drug Therapy To Transplant Patients	Georgia Health Sciences University Foundation
Hematology/Oncology	Cancer Research Center	Bhalla, Kapil	Histone Deacetylase Inhibitor Based Therapy of AML	National Cancer Institute/ NIH/ DHHS
Infectious Diseases		Newman, Cheryl	Study EPZ108859, Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet (ABC/3TC FDC) for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FDC or Maintenance of the Initial Regimen for an Additional 48 weeks in Antiretroviral-Naive HIV-1 Infected HLA-B*5701 Negative Subjects followed by an Optional 60-Week Treatment Extension Phase	GlaxoSmithKline
Infectious Diseases		Newman, Cheryl	Study EPZ108859, Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet (ABC/3TC FDC) for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FDC or Maintenance of the Initial Regimen for an Additional 48 weeks in Antiretroviral-Naive HIV-1 Infected HLA-B*5701 Negative Subjects followed by an Optional 60-Week Treatment Extension Phase	GlaxoSmithKline
Pulmonary Disease		Gossage, James	A Phase III, Randomised, Multicentre, Double Blind, Parallel-Group, Active Controlled Study to Evaluate the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg bid) Compared to Warfarin (INR 2.0-3.0) for Secondary Prevention of Venous Thromboembolism (RE-MEDY)	Boehringer Ingelheim
	Cancer Research Center	Jillella, Anand	A Multi-Center, One-Label, Exploratory Study of Bcr-Abl Kinetics in Adult Patients on Nilotinib with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) and a Suboptimal Molecular Response in Imatinib	Novartis
Nephrology		Mulloy, Laura	Study of Heart and Renal Protection (SHARP)	University of Oxford
		Chisholm, Marie	Statewide Medication Access (MAP) for Transplant Patients in Georgia	University of Georgia
Hematology/Oncology		Natarajan, Kavita	Epidemiology and Treatment of Circulating Anticoagulants in Patients with Hemophilia and von Willebrand's Disease - The HTRS Registry	Hemophilia & Thrombosis Research Society (HTRS)
	Cancer Research Center	Coleman, Teresa	A Phase 2 Open-Label Study to Investigate the Pharmacodynamics and Clinical Activity of IPI-504 in Patients with Castration Resistant Prostate Cancer Stratified by Prior Chemotherapy	Infinity Pharmaceuticals

Current Research

		Forseen, Caralee	Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Inhaled Ciprofloxacin Compared to Placebo in Subjects with Cystic Fibrosis	Bayer Pharmaceuticals
Pulmonary Disease		Su, Yunchao	Side-Stream Tobacco Smoke and Nitric Oxide Modification of Calpains in Airway Epithelial Repair	Flight Attendant Medical Research Institute, Inc.
Hematology/Oncology		Natarajan, Kavita	Prevention of the Complications of Hemophilia Through Hemophilia Treatment Centers Under the Centers for Disease Control and Prevention	Hemophilia of Georgia
Cardiology		Reed, Guy	PEACH I: Preventing Early Adverse Complications in Heart Failure - 1	Scios/Johnson & Johnson
Cardiology		Robinson, Vincent J.	D-Dimer Assay, a Possible Tool in the Evaluation of Atrial Thrombosis - APPLICANT: UZOMA N. IBEBUOGU	American Medical Association Foundation
Endocrinology & Nutrition	Center for Telehealth	Stachura, Maximillian	Insulin Pumps: An Impact Study	InHealth Institute for Health Technology Studies
	Cancer Research Center	May, Amanda	A Phase 2, Randomized, Double-Blind, Multicenter Study of Exemestane with and without SNDX-275 in Postmenopausal Women with Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer, Progressing on Treatment with a Non-Steroidal Aromatase Inhibitor	Syndax Pharmaceuticals, Inc.
		Coleman, Teresa	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction of Oral Mucositis in Subjects with Advanced Head and Neck Cancer Receiving Radiotherapy with Concurrent Chemotherapy (RT/CT)	Amgen, Inc.
Hematology/Oncology		Kutlar, Abdullah	IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome (Dose Escalation Study: Varespladib Infusion [A-001] for the Prevention of Acute Chest Syndrome in At-Risk Patients with Sickle Cell Disease and Vaso-occlusive Crisis)	Anthera Pharmaceuticals, Inc.
	Immunotherapy Center	Mellor, Andrew	Innovative Therapeutic Approaches to Inhibiting Tissue Allograft Rejection Using Donor Immune Cells Expressing Indoleamine 2,3 Dioxygenase (IDO)	MCG Foundation
Infectious Diseases		Newman, Cheryl	A Study in Underrepresented Patient Populations of Regimen Tolerability: SUPPoRT	GlaxoSmithKline
Hematology/Oncology	Cancer Research Center	Samuel, Thomas	A Phase II/III Randomized, Double-Blind Study of Paclitaxel Plus Carboplatin in Combination with Vorinostat (MK-0683) or Placebo in Patients with Stage IIIB (with Pleural Effusion) or Stable IV Non-Small Cell Lung Cancer (NSCLC)	Merck & Company
	IMMAG	Cameron, Richard	Myosin16 Expression and Function in Malignant Gliomas	Intramural Grant Program

Current Research

	IMMAG	Eroglu, Ali	Sugars as Novel Cryoprotectants for Primate Oocytes	National Institute of Child Health & Human Development/ NIH/ DHHS
Hematology/ Oncology		Kutlar, Abdullah	A Prospective, Multi-Center, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety and Effect on Induction of Fetal Hemoglobin of CC-4047 in Subjects with Sickle Cell Disease - CORE LAB	Celgene Corporation
Hematology/ Oncology		Kutlar, Abdullah	Stroke with Transfusions Changing to Hydroxyurea (SWITCH)	St. Jude Children's Research Hospital
	Molecular Chaperone	Horuzsko, Anatolij	Immunomodulatory Effects of HLA-G and its Inhibitory Receptors in Experimental Autoimmune Encephalomyelitis	National Multiple Sclerosis Society
	Molecular Chaperone	Horuzsko, Anatolij	Immunomodulatory Effects of HLA-G and its Inhibitory Receptors in Experimental Autoimmune Encephalomyelitis	National Multiple Sclerosis Society
Hematology/ Oncology	Cancer Research Center	Samuel, Thomas	A Phase I/II Study of an Anti-Tumor Vaccination Using a(1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients with Refractory or Recurrent Non-Small Cell Lung Cancer	Newlink Genetics
	IMMAG	Bollag, Wendy	Protein Kinase D as a Drug Target for Treatment of Hyperproliferative Skin Diseases	SECTR Program
	Vascular Biology Center	Bogatcheva, Natalia	The Signaling Mechanisms of 2 Methoxyestradiol-Induced Endothelial Hyperpermeability	American Heart Association
Cardiology		Reed, Guy	A Randomised, Double-Blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO - A Study of PLATelet Inhibition and Patient Outcomes]	Astra Zeneca Pharmaceuticals
	Vascular Biology Center	Verin, Alexander	ATP in Lung Endothelial Barrier Enhancement	National Heart, Lung, & Blood Institute/ NIH/ DHHS
		Mulloy, Laura	Randomized, Multi-Center, Parallel Group, Open-Label Study to Evaluate the Therapeutical Benefit of an Initially Intensified Dosing Regimen of Myfortic vs. a Standard Dose Regimen of Myfortic in Combination with Neoral and Corticosteroids in De Novo Renal Transplant Patients	Novartis
Hematology/ Oncology		Kutlar, Abdullah	Clinical Laboratory Service Agreement (Service Contract for the Titus HJ Huisman Sickle Cell Center Laboratory)	HemaQuest Pharmaceuticals, Inc.
		Jillella, Anand	Protocol for Data Reporting Requirement to a Research Database for Hematopoietic Stem Cell Transplantation (HSCT)	Center for International Bone Marrow Transplant Research

Current Research

Hematology/ Oncology		Natarajan, Kavita	Adult Comprehensive Hemophilia Care Center Program	Hemophilia of Georgia
		Mulloy, Laura	A Phase 2 Randomized, Multicenter, Active Comparator-Controlled Trial to Evaluate the Safety and Efficacy of Coadministration of CP-690,550 and Mycophenolate Mofetil/Mycophenolate Sodium in De Novo Kidney Allograft Recipients	Pfizer Pharmaceuticals
		Jillella, Anand	Eastern Cooperative Oncology Group (ECOG) Purchase Service Agreement (MUGA Scan and Data Sweep)	Eastern Coop Oncology Group
		Jillella, Anand	Eastern Cooperative Oncology Group (ECOG) Purchase Service Agreement (MUGA Scan and Data Sweep)	Eastern Coop Oncology Group
Gastroenterology & Hepatology		Schade, Robert	GIDEON Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib	Bayer Pharmaceuticals
	IMMAG	Chew, Catherine	Gastric H+ Ion Transport-Cellular Control Mechanisms	National Institute of Diabetes & Digestive & Kidney Diseases/ NIH/ DHHS
Nephrology	Immunotherapy Center	McGaha, Tracy	Marginal Zone Macrophages in the Maintenance of Peripheral Tolerance	Lupus Research Institute
	IMMAG	Dynan, William	Mechanisms and Pathways Controlling Genomic Instability in Vivo (Fellow: Wendy Kuhne)	National Institute of Environmental Health Sciences/ NIH/ DHHS
Hematology/ Oncology	Cancer Research Center	Bhalla, Kapil	In Vitro and In Vivo Profiling of LBH589 in AML, CML, and Breast Cancer Models (Pre-Clinical Animal Research Agreement)	Novartis
Hematology/ Oncology	Cancer Research Center	Samuel, Thomas	A Phase I Dose Escalation, Multi-Center, Open-Label Study of AUY922 Administered IV on a Once-Weekly Schedule in Adult Patients with Advanced Solid Malignancies Including Phase II Expansion Arms in Patients with Either HER2 Positive or ER Positive Locally Advanced or Metastatic Breast Cancer	Novartis
	Immunotherapy Center	Mellor, Andrew	Manipulating Natural Host Immunoregulation Via IDO During Viral Infection	National Institute of Allergy & Infectious Diseases/ NIH/ DHHS
		Szerlip, Harold	Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients with Septic Shock	Eli Lilly
Pulmonary Disease		Gossage, James	ARIES-3: A Phase 3, Long-Term, Open-Label, Multicenter Safety and Efficacy Study of Ambrisentan in Subjects with Pulmonary Hypertension	Gilead Sciences, Inc.
Hematology/ Oncology		Kutlar, Abdullah	P06-001 EXamination of PNH by Level Of CD59, on REd and White Blood Cells, in Bone Marrow Failure Syndromes (EXPLORE)	Alexion Pharmaceuticals, Inc.

Current Research

Hematology/ Oncology		Kutlar, Abdullah	Medical College of Georgia Sickle Cell Disease Clinical Research Network	New England Research Institute
		Mulloy, Laura	A Facilitated Access Program to Provide Everolimus (RAD) for Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation	Novartis
Nephrology		Mulloy, Laura	Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT)	Bristol-Myers Squibb Company
Nephrology		Mulloy, Laura	Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT)	Bristol-Myers Squibb Company
Cardiology		Robinson, Vincent J.	"Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses Dabigatran Etxilate with Open Label Warfarin for the Prevention of Stroke and Systemic Embolic Events in Patients with Non-Vulvular Atrial Fibrillation. A Prospective, Randomised, Open Label, Active Controlled, Multicenter, Parallel- Group Non-Inferiority Trial (RE-LY STUDY)"	Boehringer Ingelheim
Cardiology		Robinson, Vincent J.	"Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses Dabigatran Etxilate with Open Label Warfarin for the Prevention of Stroke and Systemic Embolic Events in Patients with Non-Vulvular Atrial Fibrillation. A Prospective, Randomised, Open Label, Active Controlled, Multicenter, Parallel- Group Non-Inferiority Trial (RE-LY STUDY)"	Boehringer Ingelheim
Hematology/ Oncology	Cancer Research Center	Samuel, Thomas	A Phase 1 Dose-Finding Study of the Anti-Angiogenesis Agent, AG-013736, in Combinations of Paclitaxel/Carboplatin, Weekly Paclitaxel, Docetaxel, Capecitabine, and Gemcitabine/Cisplatin in Patients with Advanced Solid Tumors	Pfizer Pharmaceuticals
Nephrology		Mulloy, Laura	Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT)	Bristol-Myers Squibb Company
Hematology/ Oncology		Kutlar, Abdullah	A Prospective, Multi-Center, Open-Label, Dose-Escalation Study To Determine the Maximum Tolerated Dose, Safety and Effect of Induction of Fetal Hemoglobin of CC-4047 in Subjects with Sickle Cell Disease.	Celgene Corporation
Endocrinolo gy & Nutrition	Center for Telehealth	Stachura, Maximillian	Community-Driven Sustainable Telehealth Innovations	Georgia Research Alliance
	Center for Biotech.& Genomic Med.	Pacholczyk, Rafal	Effect of Hyperglycemia on Effector and Regulatory CD4 T Cells in NOD Mice	Juvenile Diabetes Research Foundation International

Current Research

		Szerlip, Harold	DORADO-AC-EX - A Double-Blind, Active Controlled, Long-Term Safety Extension Study to the Phase 3 DORADO-AC Study (Protocol DAR-312) of Darusentan in Subjects with Resistant Hypertension A Double-Blind, Active Controlled, Long-Term Safety Extension Study of Optimized Doses of Darusentan in Subjects with Resistant Hypertension Despite Receiving Combination Therapy with Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine	Gilead Sciences, Inc.
		Szerlip, Harold	Effect of HMG-Co-A Reductase Inhibitor Therapy on Cardiac Troponin-T in Maintenance Hemodialysis Patients	Pfizer Pharmaceuticals
		Sharma, Gyanendra	Sanofi-Aventis, A Multi-Center, Phase 3b, Stratified, Randomized, Open-Label Clinical Trial to Evaluate the Efficacy of Intensive Apidra/Lantus Therapy Versus Sliding Scale Insulin on Infarct Size in Hyperglycemic Subjects with Anterior STEMI (ST evaluation myocardial infarction) Undergoing PCI (percutaneous coronary intervention)	Sanofi-Aventis
Pulmonary Disease		Gossage, James	A Long-Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 or AMB-321	Myogen
		Kutlar, Abdullah	Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-Up Study - Specimen Core Laboratory	Clinical Trials & Surveys Corp.
		Mulloy, Laura	Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subjects with Euvolemic Hyponatremia	CardioKine Biopharma, LLC
	Cancer Research Center	Nayak-Kapoor, Asha	A Phase 1, Open-Label, Multi-Center, Parallel Group Study to Assess the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function	Celgene Corporation
		Szerlip, Harold	DORADO-AC-EX - A Double-Blind, Active Controlled, Long-Term Safety Extension Study to the Phase 3 DORADO-AC Study (Protocol DAR-312) of Darusentan in Subjects with Resistant Hypertension A Double-Blind, Active Controlled, Long-Term Safety Extension Study of Optimized Doses of Darusentan in Subjects with Resistant Hypertension Despite Receiving Combination Therapy with Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine	Gilead Sciences, Inc.
	Molecular Chaperone	Horuzsko, Anatolij	Evaluation of HLA-G Fusion Proteins	HLA-G Technologies
	IMMAG	Dynan, William	Low Dose Radiation and Radioprotection in the Vertebrate Embryo a.k.a Mechanisms and Pathways Controlling Genomic Instability In Vivo	Department of Energy

Current Research

		White, John	Effect of Doxercalciferol on Inflammation and Endothelial Function in Patients with Stage 3B Chronic Kidney Disease	Genzyme Corporation
Hematology/ Oncology		Kutlar, Abdullah	A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of 6R-BH4 in Subjects with Sickle Cell Disease	Biomarin Pharmaceutical Inc.
Hematology/ Oncology		Kutlar, Abdullah	A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects with Multiple Myeloma	Celgene Corporation
Gastroenterology & Hepatology		Schade, Robert	A 5-Year Non-Interventional Registry Study of HUMIRA (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)	Abbott Laboratories Fund
		Kutlar, Abdullah	A Randomized, Double-Blind, Placebo-controlled Study to Assess the Safety and Activity of Pentosan Polysulfate Sodium on Microvascular Blood Flow, Vascular Endothelial Injury, and Vasooclusive Pain in Patients with Sickle Cell Disease	TRF Pharma, Inc.
		Szerlip, Harold	DORADO-AC-Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension: A Phase 3 Randomized, Double-Blind, Placebo-and Active-Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of Darusentan in Subjects with Resistant Hypertension Receiving Combination Therapy with Three or More Antihypertensive Drugs, Including a Diuretic, As Compared to Guanfacine or Placebo	Gilead Sciences, Inc.
		Szerlip, Harold	DORADO-AC-Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension: A Phase 3 Randomized, Double-Blind, Placebo-and Active-Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of Darusentan in Subjects with Resistant Hypertension Receiving Combination Therapy with Three or More Antihypertensive Drugs, Including a Diuretic, As Compared to Guanfacine or Placebo	Gilead Sciences, Inc.